Sutro Biopharma
STRO
114 hedge funds and large institutions have $342M invested in Sutro Biopharma in 2022 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 40 increasing their positions, 35 reducing their positions, and 27 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 35
0.36% more ownership
Funds ownership: 8.62% → 8.98% (+0.36%)
3% less funds holding
Funds holding: 117 → 114 (-3)
11% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 27
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
42% less capital invested
Capital invested by funds: $593M → $342M (-$251M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$24M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$12.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$10M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$5.9M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$4.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$27.1M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
-$26.4M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$16.6M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$5.61M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$5.46M |
STRO Hedge Fund Activity: Q1 2022 in Review
114 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2022, worth a combined $342M — down 42% from $593M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of STRO and 24 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 40 added.
The largest buyer was BVF Inc, adding an estimated $24M. The largest seller was SV Health Investors, exiting entirely with an estimated $27.1M sold.
- 114 institutional investors held Sutro Biopharma (STRO) as of Q1 2022, down from 117 in Q4 2021.
- Funds reported $342M of Sutro Biopharma stock for Q1 2022, down 42% quarter-over-quarter.
- 24 funds opened new Sutro Biopharma positions in Q1 2022 and 27 closed out, a net change of -3 holders.
- The largest Sutro Biopharma buyer in Q1 2022 was BVF Inc, an estimated $24M added.
- The largest Sutro Biopharma seller in Q1 2022 was SV Health Investors, an estimated $27.1M sold.
Based on aggregated 13F filings for Q1 2022.